Previous 10 | Next 10 |
-The decision by the European Commission is based on data from the L-MIND study evaluating tafasitamab in combination with lenalidomide as a treatment for patients with relapsed or refractory DLBCL - Minjuvi is a new therapeutic option for eligible DLBCL patients in the European Union (...
- The decision by the European Commission is based on data from the L-MIND study evaluating Minjuvi in combination with lenalidomide as a treatment for patients with relapsed or refractory DLBCL - Minjuvi is a new therapeutic option for eligible DLBCL patients in the European Un...
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / August 17, 2021 / MorphoSys AG (FSE:MOR; NASDAQ:MOR) announced today that Incyte, its development and commercialization partner for tafasitamab, entered into a collaboration and license agreement with a subsidiary of InnoCare for tafasitamab in Gr...
The following slide deck was published by MorphoSys AG in conjunction with their 2021 Q2 earnings call. For further details see: MorphoSys AG 2021 Q2 - Results - Earnings Call Presentation
MorphoSys AG (MOR) Q2 2021 Earnings Conference Call July 29, 2021 08:00 ET Company Participants Julia Neugebauer - Senior Director, Investor Relations Jean-Paul Kress - Chief Executive Officer Sung Lee - Chief Financial Officer Roland Wandeler - Chief Operating Officer Malte Peters - Chief Re...
Image source: The Motley Fool. MorphoSys AG (NASDAQ: MOR) Q2 2021 Earnings Call Jul 30, 2021 , 10:00 a.m. ET Operator Continue reading For further details see: MorphoSys AG (MOR) Q2 2021 Earnings Call Transcript
MorphoSys (MOR): Q2 GAAP EPS of €0.61.Revenue of €38.2M (+100% Y/Y)Press Release For further details see: MorphoSys reports Q2 results
- Monjuvi U.S. net product sales of € 14.9 million (US$ 18.0 million), 16% growth Q-Q - MorphoSys announced and subsequently completed its acquisition of Constellation Pharmaceuticals - Announced and closed ~US$ 2.0 billion strategic funding partnership with Royalty Pharma ...
IRSA Propiedades Comerciales (IRCP) -69%.Infinity Pharmaceuticals (INFI) -23% on Q2 earnings release and updates data from bladder and breast cancer trials.TRxADE HEALTH (MEDS) -20% on Q2 earnings release.Bit Digital (BTBT) -17%.Flora Growth (FLGC) -15% to f...
Dzmitry Dzemidovich/iStock via Getty Images MorphoSys (MOR) is trading ~4.8% lower after tightening its financial guidance for 2021, following a preliminary evaluation of its 2021 performance for the first six months. The company projects its group revenue for the year to be in...
News, Short Squeeze, Breakout and More Instantly...
MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that it has formally notified the Nasdaq Stock Market of its intention to voluntarily delist its American Depositary Shares (“ADSs”) from the Nasdaq Global Market and to deregister the ADSs under Section 12(b) of the Securities Ex...
MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that the company has entered into a delisting agreement with Novartis BidCo AG and Novartis AG following the successful closing of the acquisition of MorphoSys by Novartis in May 2024. Novartis BidCo Germany AG (together with Novartis BidCo AG ...
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / June 20, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) announces that Novartis BidCo Germany AG informed the MorphoSys AG Management Board of its intention to merge MorphoSys AG as transferring company into Novartis BidCo Germany AG. Novartis BidCo Germany ...